Mallik Sundaram co-founded Mitra Biotech in 2008. He serves as the President & CEO of Mitra Biotech since May 2008. Prior to Mitra, Mallik was a scientific co-founder of Momenta Pharmaceuticals (Nasdaq: MNTA) which was founded on the sequencing technology for Complex polysaccharides and glycoproteins, co-developed by Mallik at the Sasisekharan laboratory at MIT. Mallik was instrumental in developing M-Enoxaparin, Momenta’s first Billion dollar drug and three other lead drug candidates through various stages of regulatory approval in the U.S.
Mallik obtained his Ph.D. in Biotechnology from the University of Utah, Salt Lake City, UT and MBA from the Wharton Business School, University of Pennsylvania. He has been an adjunct faculty in the Department of Bioengineering (2000-2007) and the Department of Chemical Engineering (2007-present) at the Massachusetts Institute of Technology, Cambridge, MA.